Frontotemporal lobar degeneration (FTLD) is a genetically heterogenous syndrome and has been associated most recently with a hexanucleotide repeat expansion within the C9ORF72 gene. Pathogenic TDP-43 gene (TARDBP) mutations have been identified in amyotrophic lateral sclerosis, but the role of TARDBP mutations in FTLD is more contradictory. To investigate the role of TARDBP mutations in a clinical series of Finnish FTLD patients, we sequenced TARDBP exons 1 to 6 in 77 FTLD patients. No evident pathogenic mutations were found. We identified a novel heterozygous c.876_878delCAG sequence variant in 2 related patients with behavioral variant frontotemporal dementia without amyotrophic lateral sclerosis. The variant is predicted to cause an amino acid deletion of serine at position 292 (p.Ser292del). However, p.Ser292del was also found in 1 healthy middleaged control. Interestingly, both patients carried the C9ORF72 expansion. Therefore, the TARDBP variant p.Ser292del might be considered a rare polymorphism and the C9ORF72 repeat expansion the actual disease-causing mutation in the family. Our results suggest that TARDBP mutations are a rare cause of FTLD. However, the interaction of several genetic factors needs to be taken into account when investigating neurodegenerative diseases.
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(Alzheimer Dis Assoc Disord 2014; 28:190-193) F rontotemporal lobar degeneration (FTLD) is a clinically and genetically diverse dementia syndrome, with phenotypes of behavioral variant frontotemporal dementia (bvFTD), semantic dementia, and progressive nonfluent aphasia. A proportion of patients with FTLD also develop amyotrophic lateral sclerosis (ALS). The common genetic causes of FTLD, that is, mutations in microtubule-associated protein tau (MAPT) and progranulin (PGRN), are rare in Finnish patients with FTLD (Supplemental Digital Content 1, references S1 and S2, http://links.lww.com/ WAD/A30), whereas the recently discovered hexanucleotide repeat expansion within C9ORF72 explains nearly 50% of the Finnish familial FTLD and ALS cases. 1 Neuronal ubiquitin-positive cytoplasmic inclusions are the pathologic hallmark of the most common FTLD subtype (FTLD-TDP) and ALS. TDP-43 protein is the major component of these inclusions in both diseases, and it has provided evidence that the 2 diseases belong to a clinicopathologic spectrum of overlapping neurodegenerative disorders. 2 The pathogenic role of TDP-43 in neurodegeneration has been further strengthened by the identification of mutations within the coding gene, TAR DNA-binding protein (TARDBP) gene, in patients with familial and sporadic ALS (Supplemental Digital Content 1, reference S3, http://links. lww.com/WAD/A30). Mutations in TARDBP have been evaluated in several FTLD cohorts, but pathogenic TARDBP mutations have been detected only in 5 cases with FTLD, with or without ALS (Table 1) . [3] [4] [5] [6] Given the reports linking TDP-43 in the ALS-FTLD spectrum, we aimed at further investigating the prevalence and clinical features of TARDBP mutations in a cohort of Finnish patients with FTLD.
METHODS

Patients and Controls
The study group consisted of 77 patients (47% men; mean age at onset 58.5 ± 7.2 y; range, 38 to 79 y) meeting the clinical criteria for FTLD and recruited from the Memory Clinic at the Oulu University Hospital, Finland, during the years 1999 to 2010. BvFTD was the most common clinical phenotype (63%), with progressive nonfluent aphasia and semantic dementia in 25% and 12% of cases, respectively. Concomitant ALS was present in 9 (12%) patients. There were 30 (39%) patients with familial presentation, and in those with familial presentation there was a pair of siblings from 3 different families. Mutations in MAPT and PGRN were previously excluded. As a part of the recent mutation discovery study, the C9ORF72 expansion was screened in 75 of 77 patients included in this series and identified in 22 (29%) patients. 1 Control samples were obtained from 27 cognitively healthy elderly people (mean age 79.4 ± 7.2 y; range, 67 to 93 y) and 130 self-reported healthy, anonymous middleaged volunteers (mean age at blood collection 52.3 ± 5.3 y; range, 45 to 64 y) as part of blood donations at Finnish Red Cross offices in Northern Finland. The research protocols were approved by the Ethics Committees of the Northern Ostrobothnia Hospital District and the Finnish Red Cross. Written informed consent was obtained from all patients or their guardians.
Genetic Analyses
All patients were screened for exons 1 to 6 and for the flanking intronic regions of TARDBP. Genomic DNA was amplified by polymerase chain reaction and sequenced with the ABI3130xl Genetic Analyzer (Applied Biosystem, Foster City, CA) using relevant specific genomic primers. Obtained sequences were compared with the genomic DNA sequence of TARDBP (GenBank Accession Number NG_008734.1). Nucleotide changes were numbered corresponding to the largest TARDBP transcript (NM_007375.3) starting at the translation initiation codon. Protein numbering was relative to the largest TDP-43 isoform (NP_031401.1). A novel TARDBP c.876_878delCAG variant in exon 6 was screened in 157 controls by polymerase chain reaction using mismatch primers [forward 5 0 -TCAGGGTGGATTTGGTAAT:::A GAG-3 0 (: indicating the deletion CAG) and reverse 5 0 -GCATGTAGACAGTATTCCTATGGC-3 0 ] and confirmed by direct sequencing.
To investigate whether the 3 p.Ser292del carriers are descendants of a common founder, allele sharing study was performed using 7 microsatellite markers flanking 6. 
RESULTS
Mutation screening of TARDBP did not reveal any definitely pathogenic mutations. Instead, we found a novel heterozygous sequence variation: a trinucleotide deletion c.874-878del3 in exon 6, resulting in a deletion of the serine residue 292. The nucleotide sequence coding Ser292-Arg293 in TARDBP is -AGC-AGA-; trinucleotide deletion of -AGC-(c.874_876del), GC-A (875_877del) or C-AG at DNA level all 3 result at protein level in p.Ser292del leaving the sequence AGA and thus the arginine residue unaffected. It is not possible to determine exactly which of the positions is deleted; hence, the variant was arbitrarily named c.876-878delCAG (p.Ser292del) according to the most 3 0 position (Fig. 1A) . The p.Ser292del variant was identified in 2 siblings, II-3 and II-5 (Fig. 1B) . Both patients also carried the C9ORF72 expansion. At the age of 54 years, patient II-3 developed compulsive thoughts and stereotypical behavior relating to food. Patient II-5 presented with a decline in social conduct, disinhibition, depressive symptoms, and mild memory problems at the age of 47 years. Subsequently, both siblings developed severe neuropsychiatric symptoms. No signs of ALS were detected. With problems only in executive functions, the cognition of patient II-3 remained quite stable for nearly 10 years, whereas in patient II-5 marked deterioration was seen in 3 years. Their father (I-1) had died of acute myocardial infarction at the age of 60 years. In his last years, he had suffered from aggressive and impulsive behavior, but diagnosis of dementia was not made. The mother (I-2), aged 94 years, is alive and has developed mild memory problems after the age of 90 years. One sister (II-2) died at the age of 67 years, and she is reported to have suffered from progressive dementia. There was no family history of ALS. The p.Ser292del was also detected in heterozygous form in 1 healthy control (0.6%). The control carrying the variant is a man and his age at blood collection was 46 years. He reported himself healthy when participating in blood donation. Both patients with the p.Ser292del shared the 6.7 Mb haplotype around the TARDBP gene. The control with the p.Ser292del variant shared the same haplotype as the 2 patients, except for the nearest 5 0 marker, D1S2736 (see Supplemental Digital Content 2, http://links.lww.com/WAD/ A31 for the detailed results of haplotype analysis). P.Ser292 is highly conserved among animals but not in human heterogenous nuclear ribonucleoprotein (hnRNP) paralogs (see Supplemental Digital Content 3, http://links. lww.com/WAD/A32 illustrating the conservation of amino acid residues). There is a conserved series of glycine residues in human hnRNPs and TDP-43, which in TDP-43 are targets of pathogenic mutations in ALS/FTLD. P.Ser292 is an improbable phosphorylation target (17.9%, NetPhos 2.0), and deletion of this residue does not significantly change hydrophobicity of this region of the protein (not shown).
In addition, a novel intronic TARDBP variant was detected in 1 patient: insertion NG_008734.1:g. 14428_ 14429insT (NM_007375.3:c.715-74insT) located upstream of exon 6.
DISCUSSION
Mutations in TARDBP are mainly associated with ALS. Today, there are also a few reports on TARDBP mutations in patients with other neurodegenerative phenotypes, including FTLD (Table 1) . [3] [4] [5] [6] We aimed at defining the role of TARDBP in the cohort of Finnish FTLD patients. No evident pathogenic mutations were identified. However, we detected a novel TARDBP deletion variant, p.Ser292del, in a pair of siblings. This is the first description of a deletion variant in the coding region of TARDBP. The variant is located in exon 6, which seems to represent a hotspot for ALS-linked TARDBP mutations, suggesting a pathogenic role of the variant. The same residue, p.Ser292, has previously been linked to Chinese patients with familial and sporadic ALS carrying a likely pathogenic missense mutation, p.Ser292Asn (c.875G > A). 7, 8 Interestingly, both patients with the p.Ser292del of TARDBP also carried the C9ORF72 expansion. The repeat expansion has been found to be the most common cause of familial FTLD and ALS, 1 and it is assumed as the disease-causing mutation in our siblings as well. Owing to the absence of DNA samples from family members, we cannot determine whether the TARDBP deletion variant segregates with the disease.
The fact that TARDBP p.Ser292del was detected in 1 healthy middle-aged control speaks against the pathogenicity of the variant. However, we cannot exclude the possibility of him developing any cognitive or neuropsychiatric symptoms later on. The variant p.Ser292del may have some role in neurodegeneration. On the basis of our in silico analyses, the variant is unlikely to affect the phosphorylation status of the protein or local hydrophobicity. However, there is a conserved pattern of glycine residues spanning the affected p.Ser292 site that is even more prominent in human hnRNP paralogs than in TDP-43 proteins of different species (Supplemental Digital Content 3, http://links.lww.com/WAD/A32). As glycine-rich domains in hnRNPs A1 and A2/B1, and in TDP-43, are known to have a role in protein-protein interactions (Supplemental Digital Content 1, reference S4, http://links.lww.com/ WAD/A30) and small amino acids are important on protein interaction surfaces, we propose that this protein region might function in protein-protein interaction function, which is important for neuronal cells. The p.Ser292del changes the spacing of these glycine residues and therefore has a more prominent effect on this presumed interaction compared with any missense mutation affecting only 1 of the glycine residues.
Interestingly, there are now 2 studies reporting a combination of the pathogenic C9ORF72 expansion and a missense mutation of another gene: 1 study describing 2 Sardinian probands with ALS-FTLD carrying the C9ORF72 expansion and TARDBP p.Ala382Thr mutation, and the other reporting 2 expansion cases with FTLD carrying 2 novel missense mutations in PGRN (p.Tyr294Cys) and PSEN2 (p.Ile146Val). 9, 10 The ALS-FTLD proband with paternal C9ORF72 expansion and maternal TARDBP mutation had a much younger age at disease onset compared with the parents, suggesting genetic burden in the proband. 9 On the contrary, the phenotypes and the age at onset of our 2 siblings did not differ from typical bvFTD, and no signs of ALS were detected.
In conclusion, mutations in TARDBP are a rare cause of FTLD. In the present family, the C9ORF72 expansion is the probable disease-causing factor. Our data do not support a direct pathogenic role of the p.Ser292del variant in TARDBP. Nevertheless, we cannot fully exclude the possibility that the p.Ser292del variant would not have any role in the disease, for example, as a disease-modifying factor. In genetic screening studies, cases with known or suspected pathogenic mutations are often excluded in the study design. This report emphasizes that exclusion of those cases may lead to missing other genetic factors and may blur the broad genetic background behind neurodegenerative diseases.
